These new findings together advance the understanding of AML biology with respect to its metabolic characteristics and c-Myc regulation and provide a basis for developing new therapeutic strategy that target wt-IDH2 for AML treatment. This evidence concerns the gene IDH2 and acute myeloid leukemia.